Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncologists' attitudes toward KRAS testing: a multisite study.

Cancer medicine - 1 Dec 2013

Harris Julie N, Liljestrand Petra, Alexander Gwen L, Goddard Katrina A B, Kauffman Tia, Kolevska Tatjana, McCarty Catherine, O'Neill Suzanne, Pawloski Pamala, Rahm Alanna, Williams Andrew, Somkin Carol P

Abstract excerpt

Recent discoveries promise increasingly to help oncologists individually tailor anticancer therapy to their patients' molecular tumor characteristics. One such promising molecular diagnostic is Kirsten ras (KRAS) tumor mutation testing for metastatic colorectal cancer (mCRC) patients. In the curr...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Attitude of Health Personnel
Share to Communication
Share to Decision Making

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Medical Oncology

Share to Physician-Patient Relations

Share to Physicians

Share to Precision Medicine

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 24403261
DOI: 10.1002/cam4.135
PMCID: PMC3892392

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24403261-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncologists' attitudes toward KRAS testing: a multisite study.PMID 24403261Read ↗

Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia.Semantic proximity Read ↗

KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings.Semantic proximity Read ↗

Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients: A Population-based Study.Semantic proximity Read ↗

Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.Semantic proximity Read ↗

KRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis.Semantic proximity Read ↗

Assessing Oncologists' Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real-World Data.Semantic proximity Read ↗

RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres.Semantic proximity Read ↗

RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.Semantic proximity Read ↗

The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011.Semantic proximity Read ↗

Socioeconomic Determinants of the Use of Molecular Testing in Stage IV Colorectal Cancer.Semantic proximity Read ↗

Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample.Semantic proximity Read ↗

Challenges That Hinder the Translation of Clinical Advances Into Practice: Results From an International Assessment in Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.